Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

about

Monitoring of tumor vascular normalization: the key points from basic research to clinical application

P2860

Q57484416-3691DD56-9CE4-441E-9E33-386FFC5B7202

P2860

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Item

http://www.wikidata.org/entity/Q52151865

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@en

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@nl

type

Item

label

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@en

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@nl

prefLabel

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@en

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@nl

P1476

Voxel-based evidence of perfus ...... herapy/tipifarnib combination.

@en

P2093

Elizabeth Cohen-Jonathan Moyal

http://www.w3.org/2001/XMLSchema#string

Isabelle Catalaa

http://www.w3.org/2001/XMLSchema#string

Jean-Albert Lotterie

http://www.w3.org/2001/XMLSchema#string

Jonathan Khalifa

http://www.w3.org/2001/XMLSchema#string

Pierre Celsis

http://www.w3.org/2001/XMLSchema#string

Vincent Lubrano

http://www.w3.org/2001/XMLSchema#string

P2860

Improving tumour heterogeneity MRI assessment with histograms.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.

A randomized trial of bevacizumab for newly diagnosed glioblastoma

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.

P2888

s11060-015-1860-8

P304

465-473

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-015-1860-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280135177

http://www.w3.org/2001/XMLSchema#string

P698

26189058

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

about

P2860

P2860

Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921